Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 170 participants.

Also called NCT03994471

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 170 participants (planned count) (from the registry)
Sponsor
Iperboreal Pharma Srl (from the registry)
Registry
  • NCT NCT03994471
  • EudraCT 2019-004183-21
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark, Germany, Italy, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT03994471. Randomized; single masking; primary purpose treatment. Start 2022-12-14 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.
Acronym
ELIXIR
Condition
End Stage Renal Disease
Intervention (Drug)
XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght
Intervention (Drug)
1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution
Lead sponsor
Iperboreal Pharma Srl (class: industry)

Record details

Record id
cardio:ct-nct03994471
Content hash
060de8b1f6c976c28d86700c5c163c3ad958a3a6ff48829d0f03aea8b8937e4a